Seresto and its associated name Foresto

Current status:
European Commission final decision


Questions and answers on Seresto and its associated name Foresto

Outcome of a procedure under Article 13 of Regulation (EC) No 1234/2008

On 15 February 2018, the European Medicines Agency (the Agency) completed an arbitration procedure for Seresto and its associated name Foresto. The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the change to the marketing authorisation for Seresto to add a new indication can be granted.

Key facts

Approved name
Seresto and its associated name Foresto
International non-proprietary name (INN) or common name
  • imidacloprid
  • flumethrin
Associated names
Reference number
Article 13

This type of referral is triggered for a medicine that has been authorised by mutual recognition or via the decentralised procedure when there is disagreement between Member States on a variation (type II).

European Commission final decision
Opinion date
EC decision date

All documents

Document description

  • Opinion - contains the CVMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents may not always be available:

How useful was this page?

Add your rating
1 rating
4 ratings